ARCHIVED: NOT AVAILABLE FOR CREDIT
Best Practice Immunohistochemistry in Diagnosis of Urological Tumors

 

This lecture will help the practicing pathologist develop a best practice standard with regards to immunohistochemical stain usage in the urologic tract, specifically bladder, prostate and kidney. Immunohistochemistry should help guide and add to, but not dictate, a diagnosis. Thus, accurately integrating an immunopanel’s results into the clinical history, gross examination and microscopy requires understanding when to order and how to appropriately interpret immunohistochemical stains. Differentiating between benign tissue, reactive processes and various urinary tract malignancies is the focus of this lecture.

Originally presented on February 13, 2019, in Park City, Utah.

Lecture Presenter

Mahul Amin, MD

Mahul Amin, MD

Professor and Chairman of Pathology
University of Tennessee Health Science Center, Gerwin Endowed Chair for Cancer Research

Dr. Mahul Amin is an internationally recognized researcher, leading urologic pathologist and highly effective operations executive, with consistent success heading up clinical practice and research transformations in translational pathology, leading growth, and increasing industry recognition for large academic laboratories. He is an international consultant in tumors of the genitourinary tract and a world-renowned expert and educator in genitourinary pathology having co-authored the 2002 WHO classification systems for urothelial tumors and renal neoplasms; and the 2016 WHO classification systems for tumors of the prostate, bladder, kidney, penis and testis.

He has made pioneering contributions including the first major descriptions of entities in genitourinary pathology including lymphoepithelioma-like carcinoma of the bladder, micropapillary carcinoma of the bladder, acquired cystic disease associated renal cell carcinoma, clear cell-papillary renal cell carcinoma, thyroid-like carcinoma of the kidney, tubulocystic carcinoma of the kidney, intratubular large cell hyalinizing sertoli cell neoplasia of the testis, and low-grade glandular tumors of the urachus. He has authored some of the first major series and descriptions on Succinate dehydrogenase - deficient renal cell carcinoma and Fumarate hydratase- deficient renal cell carcinoma and the classification of neuroendocrine tumors of the prostate.

His scientific interests are in the discovery and validation of biomarkers in urologic malignancies for clinical personalized medicine. He has co-authored 13 books and published over 330 papers and 71 book chapters. Dr Amin’s H Index is 97 and his i10 index is 307; his work has a total of 39751 citations (data from Google Scholar March 22, 2018). Dr. Amin is a sought out speaker and has given over 360 pathology grand rounds, lectures and workshops. He has extensively spoken around the world and lectured in 30 countries and 67 cities outside of the US.

Objectives

After this presentation, participants will be able to:

  • Apply and interpret immunohistochemical stains appropriately to best support a diagnosis in urologic tumors
  • Identify potential pitfalls for immunohistochemical markers in benign, reactive and malignant urologic lesions
  • Order panels for common diagnostic dilemmas and differentials of the urologic tract

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories